Eindhoven-based Salvia BioElectronics, a clinical-stage medical machine firm innovating neuromodulation remedy for sufferers with persistent migraine, at this time introduced the profitable completion of their €53 million Sequence B financing spherical.
The spherical was led by Innovation Industries, a European DeepTech VC agency, with participation from Make investments-NL and EIC Fund. Present traders Inkef, Panakès Companions, SHS Capital, Dolby Household Ventures, BOM and Thuja Capital additionally joined the spherical.
“With the assist of this sturdy investor syndicate, we’re empowered to convey MySalvia Remedy to sufferers in determined want of recent remedy choices,” mentioned Hubert Martens, Founder and CEO of Salvia BioElectronics. “Persistent migraine is just not ‘only a headache’. It’s a debilitating neurological situation that forces individuals out of their social life, their work, and the life they need to dwell. Our mission is to revive their freedom.”
Based in 2017, Salvia BioElectronics is innovating neuromodulation remedy aiming to remodel the migraine remedy panorama. Designed to supply significant reduction, MySalvia Remedy options an ultra-thin implant that targets key nerves concerned in migraine, aiming to cut back the frequency and depth of migraine assaults.
MySalvia Remedy makes use of two ultra-thin implants, positioned simply beneath the pores and skin of the brow and the again of the top. To activate remedy, sufferers use an exterior wearable machine and easily press a button to ship focused stimulation precisely when and the place it’s wanted.
The funds will allow Salvia to finish scientific growth and put together for the business launch of MySalvia Remedy, which is presently evaluated within the RECLAIM examine, a multi-centre, double-blind, sham-controlled examine for individuals with persistent migraine. The funds additionally permit Salvia to deal with acquiring FDA market authorisation within the US and regulatory approvals in Europe and Australia.
“MySalvia Remedy is designed to supply not simply reduction, however significant and lasting impression. We imagine individuals with migraine deserve the chance to reclaim their lives. With this funding, we’re advancing towards regulatory approval and commercialisation, with the final word aim of reaching thousands and thousands of individuals affected by persistent migraine,” added Martens.
In line with Salvia, migraine is among the main causes of incapacity worldwide, leading to an estimated €96.6 billion yearly in misplaced productiveness and medical prices within the EU and US alone. Present remedy choices don’t at all times present adequate reduction, with the vast majority of persistent sufferers discontinuing their medicine inside the first yr.
“Salvia BioElectronics is redefining the migraine remedy panorama with a daring, patient-centered strategy that mixes cutting-edge neuromodulation with a chic, minimally invasive design,” mentioned Caaj Greebe, Accomplice at Innovation Industries. “At Innovation Industries, we put money into breakthrough applied sciences which have the potential to unravel essentially the most urgent real-world challenges and Salvia BioElectronics does precisely that: providing life-changing options for thousands and thousands of individuals dwelling with persistent migraine. We’re excited to associate with the Salvia crew as they advance by way of their scientific growth to ship a significant new remedy.”
Salvia’s FDA-designated Breakthrough Gadget represents a brand new remedy choice for sufferers who haven’t responded to accessible therapies. Early scientific information signifies a possible discount within the frequency and depth of migraine assaults when utilizing the corporate’s neuromodulation know-how.
Salvia’s implant is reportedly considerably much less invasive than typical know-how, which reduces surgical complexity, affected person restoration time, and gives a visually discreet answer.
The know-how additionally holds promise for treating cluster headache.
